Trial reportCirculation1980
Aspirin in coronary heart disease. The Coronary Drug Project Research Group.
Trial report in Circulation, 1980. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00000482. Cited by 14 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Coronary Drug Project
Who cites it
14 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Methods and validity indicators for measuring adherence and persistence to aspirin in secondary cardiovascular prevention: a systematic review.Frontiers in cardiovascular medicine · 2025Pooled it
- The influence of gender on the effects of aspirin in preventing myocardial infarction.BMC medicine · 2007Pooled it
- Antiplatelet therapy in the prevention of ischemic vascular events: literature review and evidence-based guidelines for drug selection.Clinical cardiology · 1999Pooled it
- North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group.BMJ (Clinical research ed.) · 1998Guideline
- Plasma levels of aspirin following effervescent and enteric coated tablets, and their effect on platelet function.European journal of clinical pharmacology · 1982Trial
- The aspirin heart disease prevention conundrum.American journal of preventive cardiology · 2025Review
- The evidence strength of a meta-analysis of aspirin for primary prevention of cancer.Journal of cancer research and clinical oncology · 2020Article
- Long-term aspirin use for primary cancer prevention: An updated systematic review and subgroup meta-analysis of 29 randomized clinical trials.Journal of Cancer · 2020Article
- Survival prospects after acute myocardial infarction in the UK: a matched cohort study 1987-2011.BMJ open · 2017Article
- The patient with cardiovascular disease: treatment strategies for preventing major events.Clinical cardiology · 2006Review
- Economic assessment of the secondary prevention of ischaemic events with lysine acetylsalicylate.PharmacoEconomics · 2000Article
- Coumadin Aspirin Reinfarction Study: Rationale and Design of the CARS Study.Journal of thrombosis and thrombolysis · 1995Article
- Lack of direct antiarrhythmic electrophysiological effects of salicylate on isolated guinea-pig myocardium.Naunyn-Schmiedeberg's archives of pharmacology · 1983Article
- Patient Adherence and the Serum Phosphate, Calcium, and Intact Parathyroid Hormone Control in Peritoneal Dialysis Patients: Effectiveness of Smart PD Care Program.Kidney diseases (Basel, Switzerland)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
0 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Coronary Drug Project Aspirin Study (CDPA), started in late 1972 and terminated in early 1974, involved men selected from three groups originally receiving dextrothyroxine or estrogen therapy in the Coronary Drug Project. All patients had a history of myocardial infarction, most of them several years earlier. Length of follow-up ranged from 10-28 months (average 22 months). A total of 1529 patients were recruited and were randomly assigned on a double-blind basis to aspirin therapy -- one 324-mg tablet three times daily or a corresponding placebo treatment. Data indicate a high level of adherence to the study protocol. No major differences were recorded in use of nonstudy medications in the two treatment groups. Overall mortality was 5.8% in the aspirin group and 8.3% in the placebo group (an observed difference of 30%). This difference, suggestive of a beneficial effect for aspirin in the treatment of post-myocardial infarction men, was not large enough to be conclusive.
Indexed as
Identifiers
7002353What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.